Table 2.

Adjusted hazard ratio^* (and 95%CI) for fracture risk associated with ADT among elderly men diagnosed with prostate cancer (n = 80 844)

	All fractures		Fractures requiring hospitalization
	Non-metastatic	Metastatic	Non-metastatic	Metastatic
No ADT	1.00	1.00	1.00	1.00
Gonadotropin-releasing hormone agonist	1.34 (1.29–1.39)	1.51 (1.36–1.67)	1.34 (1.26–1.43)	1.58 (1.35–1.85)
1–5 doses†	1.21 (1.15–1.27)	1.22 (1.07–1.39)	1.11 (1.02–1.22)	1.12 (0.90–1.40)
6–17 doses	1.31 (1.25–1.38)	1.48 (1.31–1.68)	1.29 (1.19–1.40)	1.49 (1.24–1.81)
≥ 18 doses	1.66 (1.57–1.76)	1.99 (1.75–2.27)	1.74 (1.59–1.90)	2.20 (1.82–2.67)
Orchiectomy	1.62 (1.42–1.84)	1.54 (1.26–1.88)	1.87 (1.56–2.25)	1.63 (1.21–2.18)

CI, confidence interval; ADT, androgen deprivation therapy.

^*Hazard ratios were adjusted for age at prostate cancer diagnosis, race, tumor grade, clinical T stage, presence of comorbidities, history of fracture, osteoporosis or osteopenia prior to prostate cancer diagnosis, and primary treatment. Analyses among metastatic patients were additionally adjusted for intravenous bisphosphonate use.

^†Cumulative dose from diagnosis until fracture or censoring event.